To include your compound in the COVID-19 Resource Center, submit it here.

bluebird reports updated LentiGlobin data, 3Q17 earnings

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in two patients receiving the therapy in

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE